DrugPatentWatch Database Preview
Drugs in Development Information for Ibudilast
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Ibudilast?
Ibudilast is an investigational drug.
There have been 17 clinical trials for Ibudilast.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2019.
The most common disease conditions in clinical trials are Sclerosis, Amyotrophic Lateral Sclerosis, and Alcohol Drinking. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).
There are seven hundred and seventeen US patents protecting this investigational drug and seven international patents.
Summary for Ibudilast
| US Patents | 717 |
| International Patents | 7,089 |
| US Patent Applications | 1,617 |
| WIPO Patent Applications | 889 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2019-10-01) |
| Vendors | 80 |
Recent Clinical Trials for Ibudilast
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MediciNova | Phase 2/Phase 3 |
| Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | MediciNova | Phase 1 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM | MediciNova | Phase 1/Phase 2 |
Clinical Trial Summary for Ibudilast
Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast
US Patents for Ibudilast
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibudilast | Start Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Ibudilast | Start Trial | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | Start Trial |
| Ibudilast | Start Trial | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | Start Trial |
| Ibudilast | Start Trial | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibudilast
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibudilast | Canada | 2961033 | 2034-09-11 | Start Trial |
| Ibudilast | European Patent Office | 3192791 | 2034-09-11 | Start Trial |
| Ibudilast | Japan | WO2016039408 | 2034-09-11 | Start Trial |
| Ibudilast | World Intellectual Property Organization (WIPO) | 2016039408 | 2034-09-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
